


Rev04  
Update: Mar,01,2022

**DATASHEET**

# OX40 Fc Chimera, Mouse

Cat. No.: Z03403

## Product Introduction

<b>Species</b>	Mouse
<b>Protein Construction</b>	 OX40 (Val20-Pro 211) Accession # P47741      hFc N-term                                  C-term
<b>Purity</b>	> 95% as analyzed by SDS-PAGE
<b>Endotoxin Level</b>	< 0.5 EU/μg of protein by gel clotting method
<b>Expression System</b>	HEK 293
<b>Apparent Molecular Weight</b>	~71.3 kDa, on SDS-PAGE under reducing conditions.
<b>Formulation</b>	Lyophilized from a 0.2 μm filtered solution in PBS.
<b>Reconstitution</b>	It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH <sub>2</sub> O or PBS up to 100 μg/ml.
<b>Storage &amp; Stability</b>	Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles.

## Background

**Target Background :** OX40 (TNFRSF4, CD134) is a member of the tumor necrosis factor (TNF) receptor superfamily that regulates T cell activity and immune responses. The OX40 protein contains four cysteine rich domains, a transmembrane domain, and a cytoplasmic tail containing a QEE motif. OX40 is primarily expressed on activated CD4+ and CD8+ T-cells, while the OX40 ligand (OX40L, TNFSF4, CD252) is predominantly expressed on activated antigen presenting cells. The engagement of OX40 with OX40L leads to the recruitment of TNF receptor-associated factors (TRAFs) and results in the formation of a TCR-independent signaling complex. One component of this complex, PKCθ, activates the NF-κB pathway. OX40 signaling through Akt can also enhance TCR signaling directly. Research studies indicate that the OX40L-OX40 pathway is associated with inflammation and autoimmune diseases. Additional research studies show that OX40 agonists augment anti-tumor immunity in several cancer types.

**Synonyms :** TNFRSF4; OX40; CD134; OX40L receptor,ACT35,TXGP1L

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.